the pharmaceutical industry is presently experiencing a prominent need for bioavailability enhancement technologies and services
Over the last couple of decades, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. It is considered to be one of the most important pharmacokinetic properties of a drug.
Bioavailability refers to the proportion of a drug that reaches systemic circulation unaltered, post dose administration. Additionally, it is a direct consequence of the absorption potential of an active pharmaceutical ingredient (API). The bioavailability of a drug is dependent on several factors, such as solubility, route of administration and metabolism of the drug post administration. The following figure provides different factors that have been reported to impact drug bioavailability either directly or indirectly. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. An increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html or email sales@rootsanalysis.com
the pharmaceutical industry is presently experiencing a prominent need for bioavailability enhancement technologies and services
Over the last couple of decades, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. It is considered to be one of the most important pharmacokinetic properties of a drug.
Bioavailability refers to the proportion of a drug that reaches systemic circulation unaltered, post dose administration. Additionally, it is a direct consequence of the absorption potential of an active pharmaceutical ingredient (API). The bioavailability of a drug is dependent on several factors, such as solubility, route of administration and metabolism of the drug post administration. The following figure provides different factors that have been reported to impact drug bioavailability either directly or indirectly. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. An increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html or email sales@rootsanalysis.com
